ClinicalTrials.Veeva

Menu

The Effects of Different Doses of Dexmedetomidine on Propofol Requirement for Loss of Consciousness Undergoing Bispectral Index: a Double-blinded, Placebo-controlled Trial

G

General Hospital of Ningxia Medical University

Status

Completed

Conditions

Loss of Consciousness

Treatments

Drug: dexmedetomidine 1.0 µg/kg
Drug: dexmedetomidine 0.5 µg/kg
Other: normal saline

Study type

Interventional

Funder types

Other

Identifiers

NCT02783846
MHX00123

Details and patient eligibility

About

The purpose of this study is to evaluate the effects of different dexmedetomidine on the propofol requirement for loss of consciousness undergoing bispectral index.

Full description

It has been shown that dexmedetomidine was an efficacious and safe adjuvant in general anaesthesia. Administration of dexmedetomidine during the preoperative period has been demonstrated to reduce the requirement of opioid analgesics and other sedative and hypnotic drugs.Therefore, the study is designed to measure the effect of intravenous dexmedetomidine premedication on the propofol dose requirement and bispectral index at loss of consciousness.

Enrollment

73 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • ASA physical status I-II
  • Aged 18-65 years
  • Body Mass Index 18.0~24.5 kg/m2
  • Without hearing impairment

Exclusion criteria

  • Bradycardia
  • Atrioventricular block
  • Neurologic disorder and recent use of psychoactive medication
  • Allergic to the drugs

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

73 participants in 3 patient groups, including a placebo group

Group control
Placebo Comparator group
Description:
24 eligible patients are received equal volumes of saline intravenously for 10 minutes
Treatment:
Other: normal saline
Group dexmedetomidine 0.5 µg/kg
Active Comparator group
Description:
24 eligible patients are received dexmedetomidine 0.5 µg/kg intravenously for 10 minutes
Treatment:
Drug: dexmedetomidine 0.5 µg/kg
Group dexmedetomidine 1.0 µg/kg
Active Comparator group
Description:
25 eligible patients are received dexmedetomidine 1.0 µg/kg intravenously for 10 minutes
Treatment:
Drug: dexmedetomidine 1.0 µg/kg

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems